All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Julie Vose, University of Nebraska Medical Center, Omaha, US. We asked, What are the new therapeutic strategies in Mantle cell lymphoma (MCL)?
What are the new therapeutic strategies in MCL?
Firstly, Vose discusses the efficacy and safety of novel treatment approaches, such CAR T-cell therapy, BTKis, and bispecific antibodies in MCL; brexucabtagene autoleucel, pirtobrutinib, and bispecific antibodies (specifically epcoritamab and glofitamab) for patients with R/R MCL were then discussed. With bispecific antibodies yet to be approved for R/R MCL, there remains an unmet need for treatment options in this patient group, who may require multiple treatments throughout their lifetime.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
What are the treatment options for patients with MCL who relapse after BTKi therapy?
During the European Hematology Association (EHA) 2023 Congress, the Lymphoma Hub spoke to Chan Cheah, Sir Charles Gairdner Hospital, Perth, AU. We asked, What are...
Review | Therapies available or in clinical development for patients with aggressive mantle cell lymphoma in 2020
Chemoimmunotherapy with rituximab followed by autologous stem cell transplant (auto-HSCT) has been the gold standard and the only...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox